CADILA HEALTHCARE 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE 2017-18 Annual Report Analysis
Thu, 16 Aug

CADILA HEALTHCARE has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

CADILA HEALTHCARE Income Statement Analysis

  • Operating income during the year rose 27.0% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 49.5% YoY during the fiscal. Operating profit margins witnessed a fall and down at 23.9% in FY18 as against 20.3% in FY17.
  • Depreciation charges and finance costs increased by 44.3% YoY and 104.3% YoY, respectively.
  • Other income declined by 11.8% YoY.
  • Net profit for the year grew by 20.4% YoY.
  • Net profit margins during the year declined from 16.0% in FY17 to 15.2% in FY18.

CADILA HEALTHCARE Income Statement 2017-18

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
Net SalesRs m93,765119,04927.0%
Other incomeRs m1,2841,132-11.8%
Total RevenuesRs m95,049120,18126.4%
Gross profitRs m19,04428,47549.5%
DepreciationRs m3,7335,38844.3%
InterestRs m446911104.3%
Profit before taxRs m16,14923,30844.3%
TaxRs m1,2895,644337.9%
Profit after taxRs m15,19518,29220.4%
Gross profit margin%20.323.9
Effective tax rate%8.024.2
Net profit margin%16.015.2
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



CADILA HEALTHCARE Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 61 billion as compared to Rs 53 billion in FY17, thereby witnessing an increase of 14.4%.
  • Long-term debt stood at Rs 26 billion as compared to Rs 25 billion during FY17, a growth of 3.5%.
  • Current assets rose 36% and stood at Rs 82 billion, while fixed assets rose 15% and stood at Rs 84 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 181 billion as against Rs 152 billion during FY17, thereby witnessing a growth of 19%.

CADILA HEALTHCARE Balance Sheet as on March 2018

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
NetworthRs m69,60087,44525.6
 
Current LiabilitiesRs m53,05860,72014.4
Long-term DebtRs m24,68425,5513.5
Total LiabilitiesRs m152,207180,65318.7
 
Current assetsRs m60,22382,00536.2
Fixed AssetsRs m 72,98483,70314.7
Total AssetsRs m152,207180,65318.7
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



CADILA HEALTHCARE Cash Flow Statement Analysis

  • CADILA HEALTHCARE's cash flow from operating activities (CFO) during FY18 stood at Rs 9 billion on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -10 billion on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs 515 million on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -29 million from the Rs 8 billion net cash flows seen during FY17.

CADILA HEALTHCARE Cash Flow Statement 2017-18

ParticularsNo. of months1212% Change
Year EndingMar-17Mar-18
Cash Flow from Operating ActivitiesRs m13,1179,193-29.9%
Cash Flow from Investing ActivitiesRs m-28,719-9,737-
Cash Flow from Financing ActivitiesRs m23,158515-97.8%
Net Cash FlowRs m7,556-29-
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for CADILA HEALTHCARE

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 17.9, an improvement from the EPS of Rs 14.8 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 334.8, stands at 16.5 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 5.4 times, while the price to sales ratio stands at 4.0 times.
  • The company's price to cash flow (P/CF) ratio stood at 14.9 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Sales per share (Unadj.)Rs91.6116.3
TTM Earnings per shareRs14.817.9
Diluted earnings per shareRs14.817.9
Price to Cash Flow x18.414.9
TTM P/E ratiox16.516.5
Price / Book Value ratiox5.65.4
Market CapRs m342,748342,748
Dividends per share (Unadj.)Rs3.23.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for CADILA HEALTHCARE

  • Solvency Ratios
  • Current Ratio: The company's current ratio improved and stood at 1.4x during FY18, from 1.1x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 26.6x during FY18, from 37.2x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 20.9% during FY18, from 21.8% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 22.0% during FY18, from 18.0% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 10.6% during FY18, from 10.3% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Current ratiox1.11.4
Debtors’ DaysDays8998
Interest coveragex37.226.6
Debt to equity ratiox0.40.3
Return on assets%10.310.6
Return on equity%21.820.9
Return on capital employed%18.022.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how CADILA HEALTHCARE has performed over the last 5 years, please visit here.

CADILA HEALTHCARE Share Price Performance

Over the last one year, CADILA HEALTHCARE share price has moved up from Rs 483.6 to Rs 334.8, registering a loss of Rs 148.8 or around 30.8%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,801.2 (up 0.8%). Over the last one year it has moved up from 13,214.8 to 14,801.2, a gain of 1,586 points (up 12.0%).

Overall, the S&P BSE SENSEX is up 20.2% over the year.

(To know more, check out historical annual results for CADILA HEALTHCARE and quarterly results for CADILA HEALTHCARE)

Equitymaster requests your view! Post a comment on "CADILA HEALTHCARE 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - TEVA PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS